Literature DB >> 15668963

Blood-brain barrier dysfunction in parkinsonian midbrain in vivo.

Rudie Kortekaas1, Klaus L Leenders, Joost C H van Oostrom, Willem Vaalburg, Joost Bart, Antoon T M Willemsen, N Harry Hendrikse.   

Abstract

Parkinson's disease (PD) is associated with a loss of neurons from the midbrain. The cause of PD is unknown, but it is established that certain neurotoxins can cause similar syndromes. The brain is normally protected from these noxious blood-borne chemicals by the blood-brain barrier which includes specialized proteins on the inside of blood vessels in the brain. These act as molecular efflux pumps and P-glycoprotein (P-gp) is an abundant representative. Vulnerability to PD appears codetermined by the genotype for the P-gp gene. We hypothesized that PD patients have reduced P-gp function in the blood-brain barrier. We used positron emission tomography to measure brain uptake of [(11)C]-verapamil, which is normally extruded from the brain by P-gp. Here, we show significantly elevated uptake of [(11)C]-verapamil (18%) in the midbrain of PD patients relative to controls. This is the first evidence supporting a dysfunctional blood-brain barrier as a causative mechanism in PD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15668963     DOI: 10.1002/ana.20369

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  213 in total

Review 1.  Blood-Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies.

Authors:  Loqman A Mohamed; Shashirekha Markandaiah; Silvia Bonanno; Piera Pasinelli; Davide Trotti
Journal:  AAPS J       Date:  2017-08-04       Impact factor: 4.009

Review 2.  Neuroimaging in Parkinson's disease.

Authors:  A Jon Stoessl
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

3.  Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.

Authors:  K Elisabet Ohlin; Irene Sebastianutto; Chris E Adkins; Cornelia Lundblad; Paul R Lockman; M Angela Cenci
Journal:  Neuroimage       Date:  2012-03-03       Impact factor: 6.556

4.  Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark.

Authors:  H H Nielsen; J Qiu; S Friis; L Wermuth; B Ritz
Journal:  Eur J Neurol       Date:  2012-01-17       Impact factor: 6.089

5.  Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease.

Authors:  Lissa S Brod; Jason L Aldred; John G Nutt
Journal:  Mov Disord       Date:  2012-04-16       Impact factor: 10.338

Review 6.  A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue syndrome.

Authors:  Gerwyn Morris; Michael Maes
Journal:  Metab Brain Dis       Date:  2012-06-21       Impact factor: 3.584

7.  Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood-brain barrier endothelial cells.

Authors:  Kalyan Reddy Manda; Atrayee Banerjee; William A Banks; Nuran Ercal
Journal:  Free Radic Biol Med       Date:  2010-12-28       Impact factor: 7.376

Review 8.  Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models.

Authors:  Jason R Cannon; J Timothy Greenamyre
Journal:  Neurobiol Dis       Date:  2012-07-07       Impact factor: 5.996

9.  3D self-organized microvascular model of the human blood-brain barrier with endothelial cells, pericytes and astrocytes.

Authors:  Marco Campisi; Yoojin Shin; Tatsuya Osaki; Cynthia Hajal; Valeria Chiono; Roger D Kamm
Journal:  Biomaterials       Date:  2018-07-12       Impact factor: 12.479

Review 10.  Pharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disorders.

Authors:  Sebastian A Lewandowski; Linda Fredriksson; Daniel A Lawrence; Ulf Eriksson
Journal:  Pharmacol Ther       Date:  2016-08-12       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.